Citations

Clear

4847 citation(s) found for "Tu, Eric".

Long-Term Survey to Assess Recurrence and Complications of Surgically Treated Pleomorphic Adenoma
Rourk, Katelyn S. , Hidalgo, C. , Shurtz, Anne K., Tasche, Kendall K. , Price, Daniel L., Abel, Kathryn M. Van , Moore, Eric J., Hidalgo, Cecelia M, Van Abel, Kathryn M , Yin, Linda X , Rourk, Katelyn , Price, Daniel L. , Yin, Linda X. , Moore, Eric J.

Mayo Clinic

Annals of Otology, Rhinology & Laryngology | May 19, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/00034894261453714 | PMID 42152554 Get It

Objective(s): To (1) report on the long-term recurrence rate of surgically managed pleomorphic adenoma (PA) and (2) assess long-term surgical outcomes after parotidectomy Methods: Cross-sectional survey of all patients with a pathologic diagnosis of PA who underwent surgical management in a tertiary care center from 01/1997 to 12/2023 and had access to an electronic patient portal. Surveys were delivered via electronic patient portal or phone call with 6 questions to assess recurrence and long-term surgical outcomes. Time to first recurrence and recurrence free survival were analyzed using a Kaplan-Meier curve. Results: Seven hundred-forty-five patients met inclusion criteria and received the survey, with a 56% response rate (n = 420). The clinical median follow-up length was 51 days, which extended to a median length of 6.2 years following the survey. The median change in follow-up length was 5.37 years ( P < .001). The recurrence rate was 1% at 5 years, with a median time to first recurrence of 7.54 years. 13% and 9% of responders reported facial asymmetry and incisional cosmetic concerns, respectively. 33% of patients reported experiencing Frey syndrome, which increased from 5.2% of survey responders with documented Frey syndrome at their original post-operative assessment. Conclusion: Long-term assessment of PA outcomes confirms low recurrence rates, suggesting regular surveillance of recurrence is likely unnecessary. Complaints of Frey syndrome increased in frequency with longer term follow-up, which should be considered during patient counseling. Level of Evidence: 3
C79-04 NUT Carcinoma-induced Central Airway Obstruction Treated With Pulsed Electric Field Ablation
Bugayong, M, Ortiz-Jaimes, G E, Edell, E S, Kern, R M, Garcia, S I, Bugayong, Maria Lorraine , ORTIZ-JAIMES, GABRIEL E, Edell, Eric S. , Kern, Ryan

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 18, 2026 | Volume: 212 | Issue: Supplement_1 | Pages: No page available

10.1093/ajrccm/aamag162.3561 Get It

Abstract Introduction Nuclear protein in testis (NUT) carcinoma, formerly known as NUT midline carcinoma, is a rare and highly aggressive subtype of squamous cell carcinoma characterized by NUTM1 gene rearrangements. It typically affects children and young adults and shows a predilection for midline structures of the head, neck, and thorax. We describe a rare case of NUT carcinoma in an elderly patient presenting with central airway obstruction treated with tumor debulking, devascularization, and pulsed electric field (PEF) ablation. Case An 89-year-old woman on chronic anticoagulation for atrial fibrillation presented with respiratory distress and hemoptysis requiring intubation and mechanical ventilation. Chest CT revealed a developing right lower lobe infiltrate and bronchoscopy demonstrated a non-obstructing right lower lobe endobronchial lesion. Pathology of the lesion confirmed NUT carcinoma but the patient was lost to follow-up. Two months later, she presented with altered mental status and respiratory failure. Imaging revealed a 4.6 x 2.6 cm mass at the level of the cricoid cartilage causing approximately 75% tracheal obstruction with tracheal wall invasion. She underwent rigid bronchoscopy with tumor debulking and devascularization, achieving &gt;80% tracheal patency post-procedure. EBUS-guided PEF ablation was then performed to target residual bulky tumor found in the paratracheal area. Given her age, comorbidities, and poor performance status, palliative chemotherapy was deferred and palliative radiotherapy was offered to limit tumor progression. Discussion NUT carcinoma is a rare and aggressive malignancy with a poor prognosis. This case demonstrates rapid tumor progression leading to respiratory failure within two months of initial diagnosis. Management options for malignant central airway obstruction in non-surgical candidates may include endobronchial debulking and ablative therapies. In this case, EBUS-guided PEF ablation, a non-thermal technique that delivers brief electric pulses to induce tumor apoptosis while sparing adjacent structures, was successfully used to treat residual disease with the goal of reducing marginal regrowth and maintain airway patency. PEF ablation has been described in percutaneous and bronchoscopic management of early stage non-small cell lung cancer; however, its application in central airway obstruction represents an innovative therapeutic approach. Although chemoradiation may be considered when feasible, no standard regimen exists for NUT carcinoma. It typically responds poorly to conventional therapies, underscoring the importance of complementary local treatment strategies in select patients. This case highlights the rapidly progressive course of NUT carcinoma and demonstrates the potential role of PEF ablation as a novel adjunct in the palliative management of malignant central airway obstruction. This abstract is funded by: None
C101-09 Lower Airway-to-lung Ratio Links to Neutrophil/macrophage Inflammation and Impaired Mucociliary Clearance in Current Smokers in SPIROMICS
Kelly, M E, Woodruff, P G, Curtis, J L, Paine, R, Barjaktarevic, I, Hoffman, E A, Bleecker, E R, Meyers, D A, Bowler, R P, Barr, R G, Cooper, C B, Couper, D, Han, M K, Putcha, N, Kaner, R J, Hansel, N N, O’Neal, W K, Martinez, F J, Ortega, V E, Smith, B M, Christenson, S A, Investigators, SPIROMICS, Curtis, Jeffrey L. , Hoffman, Eric A. , Meyers, Deborah A. , Barr, R. Graham , Han, MeiLan King , Kaner, R.J. , Hansel, Nadia N. , O’Neal, Wanda K. , Christenson, S A

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 18, 2026 | Volume: 212 | Issue: Supplement_1 | Pages: No page available

10.1093/ajrccm/aamag162.2028 Get It

Abstract Rationale Mismatch of airway to lung size has been implicated in chronic obstructive pulmonary disease (COPD) pathophysiology, whether arising from disproportioned growth or from acquired pathologies over the life course. Lower airway-to-lung ratio (ALR), assessed reproducibly via computed tomography (CT) as the mean airway lumen diameters (trachea-to-subsegments) divided by the cubed root of lung volume, is associated with COPD risk and mortality (all-cause, respiratory, cardiovascular, lung cancer). We sought to characterize the airway biology associated with lower ALR by profiling bronchial gene expression across current and former smokers. Methods We leveraged clinical, radiologic, and bronchial epithelial RNA sequencing data from the SPIROMICS (SubPopulations and Intermediate Outcomes Measures in COPD Study) Phase 1 Bronchoscopy Sub-study (n = 161). To analyze transcriptional differential expression (DE) between participants based on CT-assessed ALR, we utilized DESeq2 and then identified impacted pathways by Ingenuity Pathway Analysis (IPA). Generating cell-type transcriptional signatures from lung and blood single cell sequencing atlases, we also assessed association of ALR with differences in airway cellular composition. Results Across all ever-smokers, after adjustment for age, sex, height, COPD status, smoking status, and pack-years, n = 1,324 genes from airway epithelial samples exhibited DE at a false discovery rate (FDR) &lt;0.2. Per IPA, enriched pathways associated with lower ALR included neutrophilic degranulation and macrophage activity. In cell type analysis, lower ALR was associated with higher signatures of macrophages, neutrophils, dendritic cells, and B cells, and lower ciliated and club cell signatures. When we repeated DE analysis using the same covariate adjustments plus an interaction term for ALR and smoking, n = 713 DE genes were identified at FDR &lt;0.2; the association of DE with lower ALR was overwhelmingly in current rather than former smokers (3699 vs. 2 genes). By pathway and cell type analyses, the association between lower ALR and heightened inflammation (greater macrophage and neutrophil signaling) and epithelial dysregulation (downregulated ciliated and club cell function) was primarily restricted to current smokers. Conclusions In adult ever-smokers, lower ALR is associated with transcriptomic evidence of heightened neutrophil- and macrophage-driven airway inflammation and reduced ciliated and club cell expression, associations that were most evident among current smokers. Whether these cross-sectional patterns, which suggest impaired mucociliary defense and a diminished capacity to clear inhaled particulates, are the result of pre-existing reduced ALR, its cause, or both, will require further investigation. This abstract is funded by: SPIROMICS was supported by contracts from the NIH/NHLBI (HHSN268200900013C, HHSN268200900014C, HHSN268200900015C, HHSN268200900016C, HHSN268200900017C, HHSN268200900018C, HHSN268200900019C, HHSN268200900020C, 75N92024D00012), grants from the NIH/NHLBI (U01HL137880, U24HL141762, R01HL182622, R01HL144718, and R01HL093081), and supplemented by contributions made through the Foundation for the NIH and the COPD Foundation from Amgen; AstraZeneca/MedImmune; Bayer; Bellerophon Therapeutics; Boehringer-Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Chiesi Farmaceutici S.p.A.; Forest Research Institute, Inc.; Genentech; GlaxoSmithKline; Grifols Therapeutics, Inc.; Ikaria, Inc.; MGC Diagnostics; Novartis Pharmaceuticals Corporation; Nycomed GmbH; Polarean; ProterixBio; Regeneron Pharmaceuticals, Inc.; Sanofi; Sunovion; Takeda Pharmaceutical Company; Theravance Biopharma; Verona; and Mylan/Viatris.
C101-08 Discordant Airway Gene Expression of TSLP and Its Specific Receptor Subunit, CRLF2, Links CRLF2 to Mixed Granulocytic Inflammation and Lung Function Decline in SPIROMICS
Kelly, M E, Komori, K, Barjaktarevic, I, Curtis, J L, Bleecker, E R, Bowler, R P, Barr, R G, Comellas, A P, Cooper, C B, Couper, D, Han, M K, Hansel, N N, Hoffman, E A, Kaner, R J, Martinez, F J, Meyers, D A, O’Neal, W K, Ortega, V E, Paine, R, Smith, B M, Woodruff, P G, Christenson, S A, Investigators, SPIROMICS, Comellas, Alejandro P. , Comellas, Alejandro P , Curtis, Jeffrey L. , Barr, R. Graham , Han, MeiLan King , Hansel, Nadia N. , Hoffman, Eric A. , Kaner, R.J. , Meyers, Deborah A. , O’Neal, Wanda K. , Christenson, S A

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 18, 2026 | Volume: 212 | Issue: Supplement_1 | Pages: No page available

10.1093/ajrccm/aamag162.2027 Get It

Abstract Rationale Thymic stromal lymphopoietin (TSLP) is an epithelial alarmin chiefly implicated in T2 airway inflammation, though it may also participate in broader (non-T2) inflammatory processes. The utility of airway epithelial gene expression of TSLP and its specific receptor subunit, cytokine receptor-like factor 2 (CRLF2), as biomarkers of downstream inflammation and clinical outcomes remains unclear. Methods We analyzed RNA sequencing data from bronchial airway brushing obtained in phase 1 of the SPIROMICS bronchoscopy sub-study (N = 161: 23 never-smokers, 67 ever-smokers with COPD, 71 ever-smokers without COPD). We related airway TSLP and CRLF2 expression to clinical, hematologic/sputum measures, and gene-expression signatures of T2/eosinophilic and neutrophilic inflammation, including to our published T2 signature and to eosinophil and neutrophil signatures derived from single-cell atlas data. Associations used Spearman correlations and linear models adjusted for age, sex, race/ethnicity, COPD status, smoking status, and pack-years. Results CRLF2 expression correlated with gene-expression evidence of both T2/eosinophilic and neutrophilic inflammation: T2 signature (ρ = 0.26, p &lt; 0.001), eosinophil signature (ρ = 0.44, p &lt; 0.001), and neutrophil signature (ρ = 0.39, p &lt; 0.001). CRLF2 was positively associated with log sputum neutrophil count (ρ = 0.24, p = 0.024) and blood neutrophil count (ρ = 0.036, p &lt; 0.001), but not with sputum or blood eosinophil counts. Higher CRLF2 related to worse baseline lung function, particularly among current smokers, (lower post-bronchodilator FEV1: ρ = −0.21, p = 0.008), as well as greater 5-year FEV1 decline across current and former smokers (ρ = −0.22, p = 0.007). Significant findings persisted after covariate adjustment. In contrast, TSLP expression, although strongly correlated with expression of the epithelial alarmin IL33 (ρ = 0.53, p &lt; 0.001), was negatively correlated with CRLF2 (ρ = −0.24, p = 0.002) and with eosinophil and neutrophil gene-expression signatures (ρ = −0.26 and −0.33, both p &lt; 0.001). TSLP expression showed no association with sputum or blood cell counts. Conclusions In bronchial epithelium from SPIROMICS, gene expression of CRLF2, but not of TSLP, tracked with downstream alarmin-relevant inflammatory programs, consistent with a regulatory role in TSLP signaling through TSLPR, as well as with clinically meaningful outcomes. CRLF2 expression was associated with evidence of both T2/eosinophilic and neutrophilic inflammation, and with lower baseline FEV1 and accelerated FEV1 decline, suggesting engagement of a broader, clinically relevant inflammatory milieu. By contrast, epithelial TSLP transcript levels mirrored IL33 gene expression but were not associated with cellular or transcriptomic inflammation. These findings position CRLF2, rather than TSLP expression itself, as a potential airway biomarker of TSLP-axis activity and disease impact with potential implications for patient stratification as well as strategic approaches for TSLP-pathway-targeted therapies. This abstract is funded by: SPIROMICS was supported by contracts from the NIH/NHLBI (HHSN268200900013C, HHSN268200900014C, HHSN268200900015C, HHSN268200900016C, HHSN268200900017C, HHSN268200900018C, HHSN268200900019C, HHSN268200900020C, 75N92024D00012), grants from the NIH/NHLBI (U01HL137880, U24HL141762, R01HL182622, R01HL144718, and R01HL093081), and supplemented by contributions made through the Foundation for the NIH and the COPD Foundation from Amgen; AstraZeneca/MedImmune; Bayer; Bellerophon Therapeutics; Boehringer-Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Chiesi Farmaceutici S.p.A.; Forest Research Institute, Inc.; Genentech; GlaxoSmithKline; Grifols Therapeutics, Inc.; Ikaria, Inc.; MGC Diagnostics; Novartis Pharmaceuticals Corporation; Nycomed GmbH; Polarean; ProterixBio; Regeneron Pharmaceuticals, Inc.; Sanofi; Sunovion; Takeda Pharmaceutical Company; Theravance Biopharma; Verona; and Mylan/Viatris.
B101-04 Proteomics of Airway Measures: The SubPopulations and InteRmediate Outcome Measures in COPD Study (SPIROMICS)
Guzman, D E, Ruvuna, L, Sun, Y, Smith, B M, Barjaktarevic, I, Bleecker, E R, Bon, J , Couper, D, Han, M K, Hansel, N N, Hoffman, E A, Krishnan, J A, Ortega, V E, Paine, R, Wells, J M, Woodruff, P G, Bowler, R P, Barr, R G, Wells, J. Michael , Wells, J Michael , Guzman, Diana, Ruvuna, L. , Smith, B M, Han, MeiLan King , Hansel, Nadia N. , Hoffman, Eric A. , Wells, J M, Barr, R. Graham

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 18, 2026 | Volume: 212 | Issue: Supplement_1 | Pages: No page available

10.1093/ajrccm/aamag162.1895 Get It

Abstract Rationale Chronic lower respiratory diseases (CLRD), including chronic obstructive pulmonary disease (COPD), were the third-leading causes of death globally in 2019. Quantitative computed tomography (CT) measures of airway wall and lumen areas are associated with greater respiratory symptoms, reduced FEV1, accelerated lung function decline, and higher risk of incident COPD. Even in individuals without COPD, greater airway wall thickness—corresponding to smaller absolute wall and lumen areas—predicts incident COPD and CLRD-related hospitalizations and mortality. Aims To identify protein signatures and biological pathways underlying airway lumen and wall areas using cross-sectional plasma protein associations with CT measures. Methods SPIROMICS is a multicenter longitudinal case-control study that recruited 2,983 adults with COPD and a 20+ packyear smoking history and controls aged 40-80 years between 2010-2015. Standardized chest CT scans were labeled with airway measures. A total of 1,255 plasma proteins measured by SomaScan were included. Linear regression models adjusted for demographic, clinical, and imaging covariates. Significance was defined by a False Discovery Rate (FDR) p-value (q-value) &lt;0.05 using the Benjamini-Hochberg method. Replication was performed in two external cohorts with inverse variance-weighted meta-analysis. Proteins meeting nominal replication underwent elastic net regression and pathway enrichment (Gene Ontology [GO] and Reactome). Results Among 2,065 participants with CT and proteomic data (mean age 63.2 years, 46.3% women, 61.6% with COPD), proteins meeting replication were significantly associated with lumen area (2 proteins; top hit a disintegrin and metalloproteinase with thrombospondin motifs 5, q = 0.016), wall area (3 proteins; top hit leptin, q = 0.011), and percent wall area (16 proteins; top hit roundabout homolog 2, q = 0.002). Elastic net selected 2 proteins for lumen area, 3 for wall area, and 12 for percent wall area. Pathway enrichment revealed FDR-significant pathways only for percent wall area via GO (50 pathways; top hit axogenesis) and Reactome (1 pathway; diseases of glycosylation). Conclusions This study identified distinct proteins, signatures, and biological pathways associated with CT airway measures of lumen area, wall area, and percent wall area. Proteins linked to airway lumen and wall area are involved in metabolic and vasoactive processes, while those for percent wall area are involved in vascular remodeling, cell adhesion, and extracellular matrix organization—highlighting structural pathophysiologic features of COPD. These findings may inform biomarker discovery and prediction of disease onset and progression. This abstract is funded by: Funding: Daniel E. Guzman, MD, MSE was funded by T32-HL144442. SPIROMICS was supported by contracts from the NIH/NHLBI (HHSN268200900013C, HHSN268200900014C, HHSN268200900015C, HHSN268200900016C, HHSN268200900017C, HHSN268200900018C, HHSN268200900019C, HHSN268200900020C, 75N92024D00012), grants from the NIH/NHLBI (U01HL137880, U24HL141762, R01HL182622, R01HL144718, and R01HL093081), and supplemented by contributions made through the Foundation for the NIH and the COPD Foundation from Amgen; AstraZeneca/MedImmune; Bayer; Bellerophon Therapeutics; Boehringer-Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Chiesi Farmaceutici S.p.A.; Forest Research Institute, Inc.; Genentech; GlaxoSmithKline; Grifols Therapeutics, Inc.; Ikaria, Inc.; MGC Diagnostics; Novartis Pharmaceuticals Corporation; Nycomed GmbH; Polarean; ProterixBio; Regeneron Pharmaceuticals, Inc.; Sanofi; Sunovion; Takeda Pharmaceutical Company; Theravance Biopharma; Verona; and Mylan/Viatris.
Development of a Large Animal Rectovaginal Fistula Model
Westenberg, Danielle N., Sarrafian, Tiffany L. , Mahlberg, Ryan, Stalboerger, Paul G., Trabuco, Emanuel C. , Dozois, Eric J. , Occhino, John A. , Westenberg, Danielle, Mahlberg, Ryan , Behfar, Atta

Mayo Clinic

Urogynecology | May 18, 2026 | Volume: 32 | Issue: 6 | Pages: 646-651

10.1097/spv.0000000000001706 | PMID 42149670 Get It

Importance Rectovaginal fistulas (RVFs) are challenging to treat, often requiring multiple surgical interventions. Research into novel therapies is limited by the lack of a sizeable and representative animal model. Given the similarities in porcine and human vaginal and rectal tissue, pigs are an ideal species for translation to human patients. Objective The objective of this study was to develop a feasible and reproducible RVF model in pigs. Study Design Six female pigs underwent RVF creation and were divided into 3 groups according to the following methods: (1) placement of 1-inch disc magnets across the rectovaginal septum, (2) a 1-inch round defect created using electrocautery and placement of a 1-inch stainless-steel gauge stent, (3) a 1-inch round defect using electrocautery without subsequent stenting. Fistulas were evaluated at 6 weeks with measurements and photographic documentation. The animals were euthanized between 12 and 14 weeks. The primary outcome of this study was fistula patency. Secondary outcomes were fistula dimension and histologic appearance of the fistula tract. Results All pigs did well with no infection or complications related to fistula creation. Both surgical methods reliably resulted in a patent fistula at 14 weeks: cautery alone and cautery with gauge stenting. Only 1 patent fistula in the magnet group was noted at the time of euthanasia. All patent fistulas showed histologic evidence of complete epithelialization of the fistula tract. Conclusions This study demonstrates 3 safe and feasible methods for RVF creation in pigs, with 2 methods showing increased reliability.
De-Escalated Adjuvant Radiation Therapy in Patients With HPV-Positive Oropharyngeal Cancer
Hidalgo, C. , Bogan, Aaron, Rourk, Katelyn S. , Baratz, Hannah , Eyassu, Daniel G. , Price, Katharine A., Moore, Eric J. , Patel, Samir H., Hinni, Michael L., Neben-Wittich, M.A. , Garces, Yolanda I. , McGee, L.A. , Wilson, Jessica, Rwigema, Jean-Claude M., Chintakuntlawar, Ashish V., Mohammadi, Homan , Price, Daniel L., Janus, Jeffrey R. , Garcia, Joaquin J., Foote, Robert L., Tasche, Kendall K. , Ma, Daniel J., Hidalgo, Cecelia M, Baratz, Hannah Q , Neben-Wittich, Michelle A, Lester, Scott C. , Holtzman, Adam L. , Rwigema, Jean‐Claude M. , Chintakuntlawar, Ashish V. , Price, Daniel L. , García, Joaquín J., Foote, Robert L. , Abel, Kathryn M. Van , Yin, Linda X. , Routman, David M.

Mayo Clinic

JAMA Network Open | May 18, 2026 | Volume: 9 | Issue: 5 | Pages: e2612837

10.1001/jamanetworkopen.2026.12837 | PMID 42149594 Get It

Importance Standard adjuvant therapy for human papillomavirus–associated oropharyngeal squamous cell carcinoma (HPV-OPSCC) is radiation therapy 60 Gy with or without cisplatin delivered in 30 fractions during 6 weeks. A phase 3 randomized clinical trial demonstrated decreased toxic effects and improved patient-reported outcomes with de-escalated adjuvant radiation therapy (DART) compared with standard therapy; however, outcomes for patients treated in the clinical practice setting following trial adoption remain unknown. Objective To compare characteristics and oncologic outcomes of patients treated with DART during clinical trials (on study) and in clinical practice settings (off study) and report progression-free survival (PFS) by risk category. Design, Setting, and Participants This retrospective cohort study included patients treated with DART in the MC1273 and MC1675 trials and in clinical practice after study completion at a multisite tertiary care center. Patients with surgically resectable HPV-OPSCC who underwent margin-negative resection between August 20, 2013, and March 21, 2023, and were treated with DART were included in the analysis. Those with prior head and neck cancer, pT0 or pT4 disease, unknown HPV status, metastatic disease at presentation, synchronous primary tumors, induction chemotherapy, or treatment at an outside institution were excluded. Data were analyzed from July 1, 2024, to July 18, 2025. Interventions DART consisting of 30 to 36 Gy in 1.5- to 1.8-Gy fractions twice daily with docetaxel 15 mg/m 2 on days 1 and 8. Main Outcomes and Measures Progression-free survival as measured via Kaplan-Meier analysis. Results A total of 282 patients were included in the analysis: 176 (62.4%) in the on-study group and 106 (37.6%) in the off-study group (252 [89.4%] male; mean [SD] age, 59.1 [9.3] years). Both groups were predominantly male (157 [89.2%] and 95 [89.6%], respectively) and consisted mostly of never smokers (118 [67.0%] and 62 [58.5%], respectively). Pathologic features were similar between groups except for nodal stage (pN1: 155 [88.1%] on study vs 102 [96.2%] off study; pN2: 21 [11.9%] on study vs 4 [3.8%] off study; P = .02). The median follow-up times were 5.2 years (95% CI, 5.2-5.8 years) in the on-study group and 2.2 years (95% CI, 1.9-2.4 years) in the off-study group. Two-year PFS was similar (93% [95% CI, 88%-97%] on study vs 93% [95% CI, 88%-99%] off study). For patients with pN1 and no extranodal extension (ENE), 2- and 5-year PFS were 97% (95% CI, 93%-100%) and 96% (95% CI, 92%-100%), respectively. Patients with pN1 and ENE had a 2- and 5-year PFS of 93% (95% CI, 89%-98%) and 87% (95% CI, 81%-94%), respectively. Conclusions and Relevance In this retrospective cohort study of patients receiving DART on and off study, oncologic outcomes were similar between the 2 groups. Fewer patients with pN2 received DART off study, given the interim results of MC1675. Patients with pN1 and no ENE treated with DART had excellent 2- and 5-year PFS, supporting DART as a compelling treatment option in well-selected patients. An additional study that is currently underway will evaluate biomarker risk-stratified treatment of patients with pN1 and ENE receiving DART.
Resistance to novel β-lactam/β-lactamase inhibitors among carbapenem-resistant Pseudomonas aeruginosa and clinical implications in the prospective observational Pseudomonas
Gottesdiener, Lee , Li, Yixuan, Greenwood‐Quaintance, Kerryl E. , Komarow, Lauren, Arias, César A. , Cober, Eric, Herc, Erica , Kaye, Keith S., Huskins, W. Charles, Figueroa, Jairo, Vilchez, Samuel, Leroi, Marcel, Rioseco, María L., Munita, Jose M., Reyes, Jinnethe , Kreiswirth, Barry N. , Hill, Carol, Baum, Keri, Chambers, Henry F., Fowler, Vance G. , Doi, Yohei, Satlin, Michael J., Group, on behalf of the Antibacterial Resistance Leadership, Munita, José M. , Fries, Bettina C , Reyes, Jinnethe , Chen, Liang , Kreiswirth, Barry N , Villegas, Maria Virginia , Paterson, David L. , Bonomo, Robert A , Fowler, Vance G. , Patel, Robin , van Duin, David , Satlin, Michael J , Evans, Scott R , Munita, Jose M , Komarow, Lauren , Arias, César A. , Cober, Eric , Kaye, Keith S. , Huskins, W. Charles , Fries, Bettina C. , Leroi, Marcel , McCarty, Todd P , Rioseco, María Luisa, Stryjewski, Martín E. , Hill, Carol , Baum, Keri, Villegas, María Virginia , Bonomo, Robert A. , Chambers, Henry F. , Patel, Robin , Doi, Yohei , Satlin, Michael J.

Mayo Clinic

Antimicrobial Agents and Chemotherapy | May 15, 2026 | Volume: 70 | Issue: 6 | Pages: No page available

10.1128/aac.00388-25 | PMID 42138639 Get It

ABSTRACT Novel β-lactam/β-lactamase inhibitors (βL/βLIs) are important therapies for carbapenem-resistant Pseudomonas aeruginosa (CRPA). However, the global extent of resistance to these agents and the impact of resistance on patient outcomes are unclear. We therefore evaluated patients with CRPA isolates at 35 hospitals (nine countries) from December 2018 to November 2019. Antimicrobial susceptibility testing was performed at a central laboratory by agar dilution for ceftolozane-tazobactam (C/T) and ceftazidime-avibactam (CZA) and by broth microdilution for imipenem-relebactam (I/R). Characteristics and outcomes, including desirability of outcome rankings (DOOR), were compared between patients infected with isolates not susceptible vs susceptible to each agent. Of 800 CRPA isolates, susceptibility to C/T, CZA, and I/R was 69%, 67%, and 33%, respectively. USA isolates ( n = 526) were more frequently susceptible to these agents than isolates from other countries ( n = 274; C/T: 83% vs 42%; CZA: 77% vs 47%; I/R: 37% vs 23%; P < 0.001 for each comparison) and isolates with carbapenemases ( n = 157) were less frequently susceptible than isolates without carbapenemases ( n = 643; C/T: 7% vs 84%; CZA: 24% vs 77%; I/R: 6% vs 39%; P < 0.001 for each comparison). Thirty-day mortality and DOOR were similar overall in patients infected with isolates not susceptible vs susceptible to each βL/βLI. However, the adjusted probability of a better DOOR outcome for a randomly selected patient with bacteremia due to a C/T-not susceptible vs -susceptible isolate was 38.2% (95% confidence interval, 25.6%–52.7%). Resistance to novel βL/βLIs, especially I/R, is common in CRPA, particularly outside the USA and in carbapenemase-producing isolates. Additional treatment options are needed for CRPA infections.
Pregnancy history, recency of childbirth, and outcomes in young women with early-stage breast cancer
Nader-Marta, Guilherme, Zheng, Yue, Rosenberg, Shoshana M, Dibble, Kate E. , Mayer, Erica L. , Poorvu, Philip D. , Ruddy, Kathryn J, Guzman-Arocho, Yaileen D, Collins, Laura C. , Peppercorn, Jeffrey, Schapira, Lidia, Tayob, Nabihah, Come, Steven E. , Warner, Ellen, Polyak, Kornelia, Partridge, Ann H. , Zheng, Yue , Marta, Guilherme Nader , Partridge, Ann H , Mayer, Erica L , Zheng, Yue , Rosenberg, Shoshana M. , Ruddy, Kathryn J. , Guzmán‐Arocho, Yaileen D. , Peppercorn, Jeffrey , Schapira, Lidia , Valenza, Carmine , Borges, Virginia F. , Tayob, Nabihah , Warner, Ellen , Polyák, Kornélia , Winer, Eric P.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | May 14, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/jnci/djag152 | PMID 42152224 Get It

Abstract Background Breast cancer (BC) diagnosed during pregnancy or postpartum often presents with aggressive features, potentially influenced by hormonal, immunological, and tissue remodeling changes. Studies have suggested that postpartum BC may be associated with worse outcomes, though most evidence is retrospective and constrained by methodological limitations. This study evaluated associations between pregnancy history, recency of childbirth, and long-term outcomes in a prospective cohort of young patients with early-stage BC. Patients and Methods Patients aged ≤40 years with stage I–III BC enrolled in the Young Women’s Breast Cancer Study were categorized at diagnosis as nulligravid, nulliparous, pregnant, or parous (≤5 vs 5 to 10 years postpartum). Analyses were stratified by BC subtype (estrogen receptor-positive [ER+]/HER2−, HER2+, and triple-negative [TNBC]), with distant recurrence-free survival (DRFS) as the primary endpoint. Results Among 859 patients, 257 (29.9%) were nulligravid, 50 (5.8%) nulliparous, 37 (4.3%) pregnant, and 515 (60.0%) parous. Pregnant patients had proportionally more TNBC, nodal involvement, T3/T4, and grade 3 tumors. After 11.1 years median follow-up, pregnancy or postpartum status was not independently associated with DRFS in multivariable models adjusted for age, tumor characteristics, and treatment, with consistent findings across ER+/HER2−, HER2+, and TNBC subtypes. Sensitivity analyses, including further categorization of postpartum diagnoses (&lt;2 vs 2 to 5 years), yielded consistent results. Conclusions Pregnancy history and recency of childbirth were not independently associated with long-term DRFS. Despite more aggressive features at diagnosis, patients diagnosed during or after pregnancy had comparable outcomes after adjustment, suggesting no adverse prognostic impact. Clinical trial registration NCT01468246 (https://clinicaltrials.gov/study/NCT01468246? term=NCT01468246&rank=1).